Copyright Reports & Markets. All rights reserved.

Global and United States Tardive Dyskinesia (TD) Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Tardive Dyskinesia (TD) Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Valbenazine
    • 1.2.3 Amantadine
    • 1.2.4 Tetrabenazine
    • 1.2.5 Clonazepam
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Tardive Dyskinesia (TD) Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Tardive Dyskinesia (TD) Treatment Market Perspective (2015-2026)
  • 2.2 Global Tardive Dyskinesia (TD) Treatment Growth Trends by Regions
    • 2.2.1 Tardive Dyskinesia (TD) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Tardive Dyskinesia (TD) Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Tardive Dyskinesia (TD) Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Tardive Dyskinesia (TD) Treatment Players by Market Size
    • 3.1.1 Global Top Tardive Dyskinesia (TD) Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Tardive Dyskinesia (TD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Tardive Dyskinesia (TD) Treatment Revenue
  • 3.4 Global Tardive Dyskinesia (TD) Treatment Market Concentration Ratio
    • 3.4.1 Global Tardive Dyskinesia (TD) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Tardive Dyskinesia (TD) Treatment Revenue in 2019
  • 3.5 Key Players Tardive Dyskinesia (TD) Treatment Area Served
  • 3.6 Key Players Tardive Dyskinesia (TD) Treatment Product Solution and Service
  • 3.7 Date of Enter into Tardive Dyskinesia (TD) Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Tardive Dyskinesia (TD) Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Tardive Dyskinesia (TD) Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Tardive Dyskinesia (TD) Treatment Forecasted Market Size by Type (2021-2026)

5 Tardive Dyskinesia (TD) Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Tardive Dyskinesia (TD) Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Tardive Dyskinesia (TD) Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Tardive Dyskinesia (TD) Treatment Market Size (2015-2026)
  • 6.2 North America Tardive Dyskinesia (TD) Treatment Market Size by Type (2015-2020)
  • 6.3 North America Tardive Dyskinesia (TD) Treatment Market Size by Application (2015-2020)
  • 6.4 North America Tardive Dyskinesia (TD) Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Tardive Dyskinesia (TD) Treatment Market Size (2015-2026)
  • 7.2 Europe Tardive Dyskinesia (TD) Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Tardive Dyskinesia (TD) Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Tardive Dyskinesia (TD) Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Tardive Dyskinesia (TD) Treatment Market Size (2015-2026)
  • 8.2 China Tardive Dyskinesia (TD) Treatment Market Size by Type (2015-2020)
  • 8.3 China Tardive Dyskinesia (TD) Treatment Market Size by Application (2015-2020)
  • 8.4 China Tardive Dyskinesia (TD) Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Tardive Dyskinesia (TD) Treatment Market Size (2015-2026)
  • 9.2 Japan Tardive Dyskinesia (TD) Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Tardive Dyskinesia (TD) Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Tardive Dyskinesia (TD) Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Tardive Dyskinesia (TD) Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Tardive Dyskinesia (TD) Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Tardive Dyskinesia (TD) Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Tardive Dyskinesia (TD) Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Teva Pharma
    • 11.1.1 Teva Pharma Company Details
    • 11.1.2 Teva Pharma Business Overview
    • 11.1.3 Teva Pharma Tardive Dyskinesia (TD) Treatment Introduction
    • 11.1.4 Teva Pharma Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020))
    • 11.1.5 Teva Pharma Recent Development
  • 11.2 Biogen
    • 11.2.1 Biogen Company Details
    • 11.2.2 Biogen Business Overview
    • 11.2.3 Biogen Tardive Dyskinesia (TD) Treatment Introduction
    • 11.2.4 Biogen Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.2.5 Biogen Recent Development
  • 11.3 Johnson & Johnson
    • 11.3.1 Johnson & Johnson Company Details
    • 11.3.2 Johnson & Johnson Business Overview
    • 11.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Introduction
    • 11.3.4 Johnson & Johnson Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.3.5 Johnson & Johnson Recent Development
  • 11.4 GlaxoSmithKline
    • 11.4.1 GlaxoSmithKline Company Details
    • 11.4.2 GlaxoSmithKline Business Overview
    • 11.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Introduction
    • 11.4.4 GlaxoSmithKline Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.4.5 GlaxoSmithKline Recent Development
  • 11.5 Neurocrine Biosciences
    • 11.5.1 Neurocrine Biosciences Company Details
    • 11.5.2 Neurocrine Biosciences Business Overview
    • 11.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Introduction
    • 11.5.4 Neurocrine Biosciences Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.5.5 Neurocrine Biosciences Recent Development
  • 11.6 Pfizer
    • 11.6.1 Pfizer Company Details
    • 11.6.2 Pfizer Business Overview
    • 11.6.3 Pfizer Tardive Dyskinesia (TD) Treatment Introduction
    • 11.6.4 Pfizer Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.6.5 Pfizer Recent Development
  • 11.7 Novartis
    • 11.7.1 Novartis Company Details
    • 11.7.2 Novartis Business Overview
    • 11.7.3 Novartis Tardive Dyskinesia (TD) Treatment Introduction
    • 11.7.4 Novartis Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.7.5 Novartis Recent Development
  • 11.8 Sanofi
    • 11.8.1 Sanofi Company Details
    • 11.8.2 Sanofi Business Overview
    • 11.8.3 Sanofi Tardive Dyskinesia (TD) Treatment Introduction
    • 11.8.4 Sanofi Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.8.5 Sanofi Recent Development
  • 11.9 AstraZeneca
    • 11.9.1 AstraZeneca Company Details
    • 11.9.2 AstraZeneca Business Overview
    • 11.9.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Introduction
    • 11.9.4 AstraZeneca Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.9.5 AstraZeneca Recent Development
  • 11.10 Bayer AG
    • 11.10.1 Bayer AG Company Details
    • 11.10.2 Bayer AG Business Overview
    • 11.10.3 Bayer AG Tardive Dyskinesia (TD) Treatment Introduction
    • 11.10.4 Bayer AG Revenue in Tardive Dyskinesia (TD) Treatment Business (2015-2020)
    • 11.10.5 Bayer AG Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Tardive Dyskinesia (TD) Treatment Scope and Market Size
    Tardive Dyskinesia (TD) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tardive Dyskinesia (TD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Valbenazine
    Amantadine
    Tetrabenazine
    Clonazepam
    Others

    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Based on regional and country-level analysis, the Tardive Dyskinesia (TD) Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Tardive Dyskinesia (TD) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Teva Pharma
    Biogen
    Johnson & Johnson
    GlaxoSmithKline
    Neurocrine Biosciences
    Pfizer
    Novartis
    Sanofi
    AstraZeneca
    Bayer AG

    Buy now